Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19500072 | 0.95 | KDM4E (0.41) | MAPTNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL1149224 | 0.82 | TSHR (0.43) | MAPTSMN1; SMN2KDM4ETSHRCA12 | |
| SCHEMBL17813161 | 0.80 | KMT2A (0.46) | MAPTNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL6343183 | 0.79 | MAPT (0.40) | MAPTNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL19500073 | 0.76 | MAPT (0.38) | MAPTNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL4798282 | 0.76 | NOTUM (0.36) | MAPTNPC1RAB9ASMN1; SMN2NOTUM | |
| SCHEMBL5004908 | 0.75 | NOTUM (0.44) | NPC1RAB9ASMN1; SMN2PKMNFKB1 | |
| SCHEMBL4379296 | 0.74 | POLB (0.43) | MAPTNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL14164203 | 0.73 | NR1H2 (0.47) | MAPTNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL29190993 | 0.72 | KMT2A (0.53) | MAPTNPC1RAB9ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050261331-A1 | Substituted pyrrolopyridines | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | US | disclosed |
| EP-1539757-A1 | SUBSTITUTED PYRROLOPYRIDINES | AstraZeneca AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004016609-A1 | SUBSTITUTED PYRROLOPYRIDINES | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261331-A1 | Substituted pyrrolopyridines | ITK, WEE1, PDPK1 | MAPT 3515/4885NPC1 3461/4885RAB9A 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.